Kyverna Therapeutics, Inc. Common Stock (KYTX NASDAQ) stock market data APIs
$4.638
0.42(9.1%)
as of November 5, 2026
Try our APIs with
free plan!
Kyverna Therapeutics, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Prev. Close
4.638
Open
5.0621
High
5.0671
Low
4.5127
52 wk Range
4.495-13.67
Market Cap
285 M
Shares Outstanding
61 843 K
Beta
2.128
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kyverna Therapeutics, Inc. Common Stock (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kyverna Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get Kyverna Therapeutics, Inc. Common Stock Fundamental Data
Kyverna Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -157 364 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Kyverna Therapeutics, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-11-11
- EPS/Forecast: -0.68
Get Kyverna Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kyverna Therapeutics, Inc. Common Stock News
New
BioMarin Appoints Cara Bauer as Chief People Officer
Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ ...
Kyverna Therapeutics Sinks 13%: Here’s Why
Quick Read KYTX dropped 12% after JPMorgan trimmed its price target to $29, despite beating Q1 estimates and initiating a rolling BLA for miv-cel targeting a 2027 launch. BEAM slid 8% from a 52-week ...
Kyverna Therapeutics’ (KYTX) Insights into Stiff Person Syndrome and Beyond
Jacob Funds, a mutual fund company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The recent quarter began against the backdrop of the war in the Middl...
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
Pharmaceutical companies can offer investors huge returns if treatments under development become blockbuster drugs. Choosing between a speculative clinical-stage play and a dominant cash-flow engine r...
Get Kyverna Therapeutics, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.